Connection
Paul Toren to Microsomes, Liver
This is a "connection" page, showing publications Paul Toren has written about Microsomes, Liver.
|
|
Connection Strength |
|
![](https://researchers.childrensmercy.org/Framework/Images/connection_left.gif) |
|
![](https://researchers.childrensmercy.org/Framework/Images/connection_right.gif) |
|
0.204 |
|
|
|
-
Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos. 2011 Aug; 39(8):1370-87.
Score: 0.094
-
Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
Score: 0.045
-
Barbara JE, Kazmi F, Muranjan S, Toren PC, Parkinson A. High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling. Drug Metab Dispos. 2012 Oct; 40(10):1966-75.
Score: 0.026
-
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011 Nov; 39(11):2020-33.
Score: 0.024
-
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006 Jan; 34(1):191-7.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|